Hyponatraemia in cancer: association with type of cancer and mortality

Zeinah, Ghaith Farid Abu; Al‐Kindi, Sadeer G.; Hassan, Azza; Allam, Ayman

doi:10.1111/ecc.12187

Cited by 48 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, it was found an independent inverse relationship between sNa levels and mortality in patients with chronic diseases, also in case of mild hyponatremia . Similar findings were reported in many studies in the oncology setting . It was even hypothesized that cancer‐related hyponatremia may adversely affect the response to anticancer‐targeted treatment, suggesting the potential benefit resulting from an early detection and proper treatment of the disorder.…”

Section: Introductionsupporting

confidence: 76%

“…12 Similar findings were reported in many studies in the oncology setting. 1,6,13 It was even hypothesized that cancer-related hyponatremia may adversely affect the response to anticancer-targeted treatment, 14 suggesting the potential benefit resulting from an early detection and proper treatment of the disorder. The degree and the duration of hyponatremia, along with the presence and severity of symptoms, have to be simultaneously considered in order to select the optimal treatment for each patient.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Urea in cancer patients with chronic SIAD‐induced hyponatremia: Old drug, new evidence

Nervo

D’Angelo

Rosso

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Background Syndrome of inappropriate antidiuresis (SIAD) is the main cause of hyponatremia in cancer patients. International guidelines indicate urea as an interesting option for chronic SIAD. Nevertheless, strong data to support its use are lacking, and its role in oncologic patients has not been described so far. Material and Methods We retrospectively analysed 36 cancer patients affected by moderate or profound SIAD‐induced chronic hyponatremia, who started oral urea (initial daily dose 15 g or 30 g) without fluid restriction between July 2013 and July 2018. We analysed mean serum sodium (sNa) increase after 24 hours and percentages of patients who reached eunatremia within 14, 30 and 60 days of treatment, stratifying according to the degree of hyponatremia at diagnosis. Clinical evaluation and biochemical assessment were periodically performed. Results Mean sNa was 123 [±4] mmol/L at baseline; after 24 hours of treatment, a mean increase of 5 [±3] mmol/L was observed. Eunatremia was reached by 55.6%, 86.1% and 91.7% patients within 14, 30 and 60 days of treatment, respectively. Trends in sNa normalization were similar in patients with moderate and profound hyponatremia at diagnosis. Rapid sNa overcorrection was avoided in all cases. Urea was interrupted within the first 2 months of treatment in 10 patients, in half cases for rapid neoplastic progression and in the remaining patients for the drug taste. Conclusions In our study, urea was effective in correcting chronic hyponatremia among cancer patients with SIAD. Almost all patients reached eunatremia within the first month of therapy, and urea was globally well tolerated.

show abstract

Section: Introductionsupporting

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Urea in cancer patients with chronic SIAD‐induced hyponatremia: Old drug, new evidence

Nervo

D’Angelo

Rosso

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Previous studies reported that hyponatremia (<135 mEq/L) was present in 47% of newly admitted cancer patients, 2) and 3.7-33.8% of cancer patients had serum sodium concentrations below 130 mEq/L. 3,4) In particular, prostate, pancreatic, and small cell lung cancers were frequently associated with the onset of hyponatremia. 4) Administration of cisplatin (CDDP), a platinum anticancer agent, has been related to the development of hyponatremia, although renal failure, nausea, vomiting, and ototoxicity were the major adverse events.…”

Section: Introductionmentioning

confidence: 98%

Risk Factors for Severe Hyponatremia Related to Cisplatin: A Retrospective Case-Control Study

Hatakeyama

Shida

Yamaguchi

2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Onset of severe hyponatremia following cisplatin (CDDP) administration has been previously reported. However, the risk factors associated with hyponatremia still remain unclear. We conducted a retrospective, single-center, case-control study to identify independent risk factors of severe hyponatremia in patients with various types of cancers. Adult patients who received intravenous CDDP administration between January 2012 and December 2017 met the inclusion criteria. The investigators recorded patients' demographics and clinical information retrospectively, and assessed the lowest serum sodium level within 21 d of the first CDDP administration. Risk factors for grade ≥3 hyponatremia were examined via a logistic regression analysis. Among a total of 472 patients, fifty patients (10.6%) developed grade ≥3 hyponatremia. Univariate analysis revealed that age (≥65 years), presence of small cell lung or esophageal cancer, and lower sodium concentrations in the serum (<138 mEq/L) were significantly associated with grade 3 and 4 hyponatremia. Additionally, multivariable logistic regression analysis showed that the presence of small cell lung cancer (adjusted odds ratio, 3.26; 95% confidence interval (CI), 1.07-10.00) and lower sodium concentrations in the serum (<138 mEq/L) (adjusted odds ratio, 6.18; 95%CI, 3.21-11.90) were independent risk factors of grade 3 and 4 hyponatremia. Thus, serum sodium concentrations in patients with these risk factors should be closely monitored after CDDP administration.

show abstract

“…This late diagnosis and treatment pattern may therefore be related to inadequate awareness about cancer prevention and screening programs available in Saudi communities [28]. Currently, there are more than 15 oncology care settings in the KSA offering a variety of services including: intensive cancer care management units, consultation services, routine screening, cancer therapy, rehabilitation, home healthcare programs, outpatient clinics, and supportive care services (diet center, physical therapy, patient education, pharmacy, and both institutional units for palliative care with translation and religious authorities to attend the spiritual needs of the terminally ill cancer patients) as well as home-based care [19,29]. The first palliative care program began more than 20 years ago at King Faisal Specialist Hospital and Research Center, Riyadh and programs are now available in a number of hospitals serving more than 5,000 patients annually [30].…”

Section: Cancer Care In the Kingdom Of Saudi Arabiamentioning

confidence: 99%

Overview of Cancer Care and Oncology Nursing in the Kingdom of Saudi Arabia

Wazqar¹,

Kerr²,

Regan³

et al. 2017

AJNS

View full text Add to dashboard Cite

Abstract:Cancer prevalence is increasing in the Kingdom of Saudi Arabia. While the exact etiology of this trend is unknown, it can perhaps be partially attributed to an increased life expectancy and changes in lifestyle habits. One of the main challenges to the provision of appropriate cancer and palliative care is the critical shortage of oncology healthcare professionals, including nurses. The Kingdom of Saudi Arabia is characterized by its Islamic faith, culture, and unique traditions that may contribute to uniquely stressful situations for oncology nurses working in Saudi oncology care settings. This article provides an overview of cancer care and oncology nursing in the Kingdom of Saudi Arabia based on literature reporting challenges experienced by nurses delivering this care within the Saudi Arabian healthcare system and its cancer care services. Published literature written in English on cancer care and oncology nurses in the Kingdom of Saudi Arabia were identified through a search of publicly available databases such as Medline, CINAHL, and Google Scholar as well as government sources. Reference lists were hand searched. Search terms used were Kingdom of Saudi Arabia, Saudi Arabian healthcare system, nursing education, nursing, Saudi nurses, oncology nursing, cancer, and cancer care. Common challenges facing oncology nursing in the Kingdom of Saudi Arabia are related to high job demands, staff shortages, communication and language barriers, and cultural differences that may lead to stressful work environments and reduce the quality of care provided to their patients. While many steps have been undertaken by the Saudi Ministry of Health to reform the healthcare system, a number of challenges remain. The need for greater availability of cancer care and palliative care settings in all Saudi regions is strongly indicated. Nursing administrators/managers should take these factors into consideration to enhance the Saudi oncology care nursing work environment and to improve the quality of nursing care for patients with cancer and their families.

show abstract

Hyponatraemia in cancer: association with type of cancer and mortality

Cited by 48 publications

References 34 publications

Urea in cancer patients with chronic SIAD‐induced hyponatremia: Old drug, new evidence

Urea in cancer patients with chronic SIAD‐induced hyponatremia: Old drug, new evidence

Risk Factors for Severe Hyponatremia Related to Cisplatin: A Retrospective Case-Control Study

Overview of Cancer Care and Oncology Nursing in the Kingdom of Saudi Arabia

Contact Info

Product

Resources

About